The diabetic β-cell: Hyperstimulated vs. hyperexcited

Diabetes, Obesity and Metabolism

Volumn 14, Issue SUPPL.3, 2012, Pages 129-135

  Nichols, C G ^a   Remedi, M S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Diabetes; Excitability; Function; Glucose; Glucotoxicity; Insulin; Islets; Membrane; Mice; Neonatal

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; GLUCOSE; INSULIN;

CELL DEATH; CELL FUNCTION; CELL STIMULATION; DIABETES MELLITUS; ELECTROSTIMULATION; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PANCREAS ISLET BETA CELL; REVIEW;

EID: 84865592405     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01655.x     Document Type: Review

References (79)

1. Dukes ID, Philipson LH. K+ channels: generating excitement in pancreatic beta-cells. Diabetes 1996; 45: 845-853.
2. Rorsman P, Trube G. Calcium and delayed potassium currents in mouse pancreatic beta-cells under voltage-clamp conditions. J Physiol 1986; 374: 531-550.
3. Philipson LH. Beta-cell ion channels: keys to endodermal excitability. Horm Metab Res 1999; 31: 455-461.
4. Su J, Yu H, Lenka N, Hescheler J, Ullrich S. The expression and regulation of depolarization-activated K+ channels in the insulin-secreting cell line INS-1. Pflugers Arch 2001; 442: 49-56.
5. Ashcroft FM, Rorsman P. ATP-sensitive K+ channels: a link between β-cell metabolism and insulin secretion. Biochem Soc Trans 1990; 18: 109-111.
6. MacDonald PE, Joseph JW, Rorsman P. Glucose-sensing mechanisms in pancreatic beta-cells. Philos Trans R Soc Lond B Biol Sci 2005; 360: 2211-2225.
7. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005; 5: 275-286.
8. Heit JJ, Apelqvist AA, Gu X et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443: 345-349.
9. Jhala US, Canettieri G, Screaton RA et al. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev 2003; 17: 1575-1580.
10. Bernal-Mizrachi E, Wice B, Inoue H, Permutt MA. Activation of serum response factor in the depolarization induction of Egr-1 transcription in pancreatic islet beta-cells. J Biol Chem 2000; 275: 25681-25689.
11. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29: 351-366.
12. Grill V, Bjorklund A. Overstimulation and beta-cell function. Diabetes 2001; 50(Suppl. 1): S122-124.
13. Trube G, Rorsman P, Ohno ST. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Arch 1986; 407: 493-499.
14. Elouil H, Bensellam M, Guiot Y et al. Acute nutrient regulation of the unfolded protein response and integrated stress response in cultured rat pancreatic islets. Diabetologia 2007; 50: 1442-1452.
15. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008; 9: 329-343.
16. Khaldi MZ, Guiot Y, Gilon P, Henquin JC, Jonas JC. Increased glucose sensitivity of both triggering and amplifying pathways of insulin secretion in rat islets cultured for 1 wk in high glucose. Am J Physiol Endocrinol Metab 2004; 287: E207-217.
17. Remedi MS, Nichols CG. Hyperinsulinism and diabetes: genetic dissection of beta cell metabolism-excitation coupling in mice. Cell Metab 2009; 10: 442-453.
18. + channels. J Gen Physiol 2006; 127: 467-480.
19. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999; 42: 903-919.
20. Nichols CG, Shyng SL, Nestorowicz A et al. Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 1996; 272: 1785-1787.
21. Aguilar-Bryan L, Nichols CG, Wechsler SW et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 1995; 268: 423-426.
22. Shyng S, Ferrigni T, Nichols CG. Regulation of KATP channel activity by diazoxide and MgADP. Distinct functions of the two nucleotide binding folds of the sulfonylurea receptor. J Gen Physiol 1997; 110: 643-654.
23. Gribble FM, Tucker SJ, Ashcroft FM. The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J 1997; 16: 1145-1152.
24. Miki T, Nagashima K, Tashiro F et al. Defective insulin secretion and enhanced insulin action in KATP channel- deficient mice. Proc Natl Acad Sci USA 1998; 95: 10402-10406.
25. Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J. Sur1 knockout mice. A model for K(ATP) channel-independent regulation of insulin secretion. J Biol Chem 2000; 275: 9270-9277.
26. Shiota C, Larsson O, Shelton KD et al. Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. J Biol Chem 2002; 277: 37176-37183.
27. Koster JC, Remedi MS, Flagg TP et al. Hyperinsulinism induced by targeted suppression of beta cell KATP channels. Proc Natl Acad Sci USA 2002; 99: 16992-16997.
28. Miki T, Tashiro F, Iwanaga T et al. Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. Proc Natl Acad Sci 1997; 94: 11969-11973.
29. Oyama K, Minami K, Ishizaki K, Fuse M, Miki T, Seino S. Spontaneous recovery from hyperglycemia by regeneration of pancreatic beta-cells in Kir6.2G132S transgenic mice. Diabetes 2006; 55: 1930-1938.
30. Remedi MS, Rocheleau JV, Tong A et al. Hyperinsulinism in mice with heterozygous loss of K(ATP) channels. Diabetologia 2006; 49: 2368-2378.
31. Nichols CG, Koster JC, Remedi MS. Beta-cell hyperexcitability: from hyperinsulinismto diabetes. Diabetes Obes Metab 2007; 9(Suppl. 2): 81-88.
32. Remedi MS, Nichols CG. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 2008; 5: e206.
33. Koster JC, Sha Q, Shyng S, Nichols CG. ATP inhibition of KATP channels: control of nucleotide sensitivity by the N-terminal domain of the Kir6.2 subunit. J Physiol 1999; 515: 19-30.
34. Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG. Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. Cell 2000; 100: 645-654.
35. Gloyn AL, Pearson ER, Antcliff JF et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838-1849.
36. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005; 54: 2503-2513.
37. Remedi MS, Kurata HT, Scott A et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus. Cell Metab 2009; 9: 140-151.
38. Girard CA, Wunderlich FT, Shimomura K et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest 2009; 119: 80-90.
39. Herrera PL. Defining the cell lineages of the islets of Langerhans using transgenic mice. Int J Dev Biol 2002; 46: 97-103.
40. Zhang H, Fujitani Y, Wright CV, Gannon M. Efficient recombination in pancreatic islets by a tamoxifen-inducible Cre-recombinase. Genesis 2005; 42: 210-217.
41. Benninger RK, Remedi MS, Head WS, Ustione A, Piston DW, Nichols CG. Defects in beta cell Ca(2)+signalling, glucose metabolism and insulin secretion in a murine model of K(ATP) channel-induced neonatal diabetes mellitus. Diabetologia 2011; 54: 1087-1097.
42. McCormack K, Lin JW, Iverson LE, Rudy B. Shaker K+channel subunits from heteromultimeric channels with novel functional properties. Biochem Biophys Res Comm 1990; 171: 1361-1371.
43. Wiederkehr A, Wollheim CB. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology 2006; 147: 2643-2649.
44. Robb-Gaspers LD, Burnett P, Rutter GA, Denton RM, Rizzuto R, Thomas AP. Integrating cytosolic calcium signals into mitochondrial metabolic responses. EMBO J 1998; 17: 4987-5000.
45. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003; 52: 581-587.
46. Jonas JC, Laybutt DR, Steil GM et al. High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells. J Biol Chem 2001; 276: 35375-35381.
47. Efanova IB, Zaitsev SV, Zhivotovsky B et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998; 273: 33501-33507.
48. Bjorklund A, Lansner A, Grill VE. Glucose-induced [Ca2+]i abnormalities in human pancreatic islets: important role of overstimulation. Diabetes 2000; 49: 1840-1848.
49. Laybutt DR, Glandt M, Xu G et al. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem 2003; 278: 2997-3005.
50. Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 2005; 54: 2755-2763.
51. Zraika S, Aston-Mourney K, Laybutt DR et al. The influence of genetic background on the induction of oxidative stress and impaired insulin secretion in mouse islets. Diabetologia 2006; 49: 1254-1263.
52. Jonas JC, Bensellam M, Duprez J, Elouil H, Guiot Y, Pascal SM. Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes. Diabetes Obes Metab 2009; 11(Suppl. 4): 65-81.
53. Bensellam M, Van Lommel L, Overbergh L, Schuit FC, Jonas JC. Cluster analysis of rat pancreatic islet gene mRNA levels after culture in low-, intermediate- and high-glucose concentrations. Diabetologia 2009; 52: 463-476.
54. Donath MY, Ehses JA, Maedler K et al. Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005; 54(Suppl. 2): S108-113.
55. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005; 54(Suppl. 2): S97-107.
56. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001; 50(Suppl. 1): S154-159.
57. Malaisse WJ. The beta cell in NIDDM: giving light to the blind. Diabetologia 1994; 37(Suppl. 2): S36S-42.
58. Poitout V. Glucolipotoxicity of the pancreatic beta-cell: myth or reality? Biochem Soc Trans 2008; 36: 901-904.
59. Aguilar-Bryan L, Bryan J, Nakazaki M. Of mice and men: K(ATP) channels and insulin secretion. Recent Prog Horm Res 2001; 56: 47-68.
60. Huopio H, Shyng SL, Otonkoski T, Nichols CG. K(ATP) channels and insulin secretion disorders. Am J Physiol Endocrinol Metab 2002; 283: E207-216.
61. Stanley CA. Advances in diagnosis and treatment of hyperinsulinism in infants and children. J Clin Endocrinol Metab 2002; 87: 4857-4859.
62. Dunne MJ, Cosgrove KE, Shepherd RM, Aynley-Green A, Lindley KJ. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev 2004; 84: 239-275.
63. Kane C, Shepherd RM, Squires PE et al. Loss of functional KATP channels in pancreatic beta-cells causes persistent hyperinsulinemic hypoglycemia of infancy (Comment). Nat Med 1996; 2: 1344-1347.
64. Huopio H, Vauhkonen I, Komulainen J, Niskanen L, Otonkoski T, Laakso M. Carriers of an inactivating beta-cell ATP-sensitive K(+) channel mutation have normal glucose tolerance and insulin sensitivity and appropriate insulin secretion. Diabetes Care 2002; 25: 101-106.
65. Shyng SL, Ferrigni T, Shepard JB et al. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes 1998; 47: 1145-1151.
66. de Lonlay P, Fournet JC, Touati G et al. Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002; 161: 37-48.
67. Henwood MJ, Kelly A, MacMullen C et al. Genotype-phenotype correlations in children with congenital hyperinsulinism due to recessive mutations of the adenosine triphosphate-sensitive potassium channel genes. J Clin Endocrinol Metab 2005; 90: 789-794.
68. Lin Y-W, MacMullen C, Ganguly A, Stanley CA, Shyng S-L. A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels. J Biol Chem 2006; 281: 3006-3012.
69. Grimberg A, Ferry RJ Jr, Kelly A et al. Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes 2001; 50: 322-328.
70. Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab 1995; 80: 386-392.
71. Pearson ER, Flechtner I, Njolstad PR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467-477.
72. Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 2011; 60: 2515-2522.
73. Greenwood RH, Mahler RF, Hales CN. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1976; 307: 444-447.
74. Qvigstad E, Kollind M, Grill V. Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes. Diabet Med 2004; 21: 73-76.
75. Alvarsson M, Sundkvist G, Lager I et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003; 26: 2231-2237.
76. Alvarsson M, Sundkvist G, Lager I et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008; 10: 421-429.
77. Bjork E, Berne C, Kampe O, Wibell L, Oskarsson P, Karlsson FA. Diazoxide treatment at onset preserves residual insulin secretion in adults with autoimmune diabetes. Diabetes 1996; 45: 1427-1430.
78. Ortqvist E, Bjork E, Wallensteen M et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004; 27: 2191-2197.
79. Radtke M, Kollind M, Qvigstad E, Grill V. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. Diabet Med 2007; 24: 172-177.